Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Multiple Myeloma

March 2, 2020

Strategies for Management of Transplant-Ineligible Patients
Patients who are ineligible for transplant are mostly the elderly patients. The treatment options have vastly improved for elderly patients with multiple myeloma but the clinicians still need to personalize treatment, as this group is highly heterogeneous. Management of myeloma in this age group requires a different approach to that in younger patients to maximize both quality and length of life. Many factors such as comorbidities, performance status, mental status, polypharmacy, renal functions, frailty scores, etc, need to be taken into account while selecting treatments. It is also important to understand challenges with management of disease with high-risk cytogenetics and strategies available to overcome the poor prognosis in these individuals. The decision to initiate combination therapy involves a multidisciplinary team considering all available diagnostic and clinical information, and in discussion with the patient and their family. Close attention from a multidisciplinary team in important to provide adequate supportive care so the patient has maximum benefit of the treatment. As tools for the assessment of minimal residual disease (MRD) (such as next-generation sequencing, next-generation flow cytometry, or PET-CT) are becoming widely available, it is important to understand the role of MRD monitoring in the outcome of transplant-ineligible patients. 

Discussing specific patient cases, providing the rationale for the treatment choices based on expert experience and recent data from trials, and outlining strategies to provide adequate supportive care will assist clinicians treating transplant ineligible and elderly patients with multiple myeloma in making optimal treatment decisions and improving patient outcomes.

Target Audience

This program is designed to meet the educational needs of physicians, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Summarize the first-line treatment options available for transplant-ineligible patients with multiple myeloma.
  • Identify key patient and clinical factors that influence first-line treatment selection for transplant-ineligible patients with multiple myeloma.
  • Provide appropriate supportive care both for symptom control and management of disease-specific complications..
Additional information
Supporters: 

This activity is supported by an educational grant from:

  • AstraZeneca
  • Celgene Corporation
  • Clovis Oncology, Inc.
  • Eisai
  • Genomic Health, Inc.
  • Lilly
  • Novartis
  • Sanofi Genzyme
  • Taiho Oncology, Inc
  • TESARO

This activity is supported by an independent medical education grant from:

  • Advanced Accelerator Applications, a Novartis company
  • Bristol-Myers Squibb
  • Pharmacyclics LLC and Janssen

This activity is supported by an independent educational grant from:

  • AbbVie
  • Astellas and Pfizer, Inc.
  • Merck  & Co., Inc.

This activity is supported by a medical education grant from Exelixis, Inc.

This activity is supported by an unrestricted educational grant from Gilead Sciences, Medical Affairs.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
01/14/2020
Course expires: 
05/31/2020
Event starts: 
03/02/2020 - 1:00pm
Event ends: 
03/02/2020 - 2:00pm
Cost:
$0.00

Noopur Raje, MD
Massachusetts General Hospital Cancer Center

Cindy C. Harrington, NP
Massachusetts General Hospital Cancer Center

 

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions  
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers  
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures
The faculty listed below discloses no relevant financial relationships:
Cindy C. Harrington, NP

The faculty listed below disclose the following relevant financial relationships:
Noopur Raje, MD
Amgen, Inc: Steering Committee/Advisory Board
Amgen-Onyx: Consulting Fee
AstraZeneca Pharmaceuticals LP: Grant/Research Support
bluebird bio: Consulting Fee
Bristol-Myers Squibb Company: Consulting Fee
Celgene Corporation: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee
Merck & Co., Inc.: Consulting Fee
Millennium Pharmaceuticals, Inc.: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Roche Laboratories, Inc.: Steering Committee/Advisory Board
Takeda Pharmaceuticals North America, Inc.: Consulting Fee

NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein

The NCCN Clinical staff listed below discloses no relevant financial relationships:
Rashmi Kumar, PhD

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-20-024-L01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.0 CE contact hour. Activity Code: I00041097; Approval #: 200136005

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

This webinar was presented live one time only on Monday, March 2, 2020, from 1:00 - 2:00 PM Eastern Standard Time (EST) (UTC -5).

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing